慢性心力衰竭临床治疗的回顾及展望  

Review and prospect of clinical treatment of chronic heart failure

作　　者：李家昊 陈文亮 陈庞何 许锦荣 LI Jia-hao;CHEN Wen-liang;CHEN Pang-he;XU Jin-rong(The First Clinical Medical College,Guangdong Medical University,Zhanjiang 524000,Guangdong,China;不详)

机构地区：[1]广东医科大学第一临床医学院,广东湛江524000 [2]广东医科大学附属第二医院心血管内科二区,广东湛江524000

出　　处：《广东医学》2024年第6期794-800,共7页Guangdong Medical Journal

基　　金：湛江市科技发展专项资金竞争性分配项目(2021A05090,2022A01132)。

摘　　要：慢性心力衰竭通常标志着大部分心血管疾病进入其终末阶段,具有患病率高、预后极其不利等特点。在药物治疗上,“金三角”方案被普遍视为治疗慢性心力衰竭的经典策略,近年来,随着大量的临床研究数据的公布,慢性心衰“新四联”疗法及可溶性鸟苷酸环化酶激动剂维立西呱等新型治疗药物开始应用于临床。一系列的生物标志物被发现,它们与慢性心衰患者的预后密切相关,如SERCA2a、中性粒细胞明胶酶相关脂质运载蛋白、生长分化因子15等。这些新疗法及生物标志物的发现有助于提高慢性心力衰竭患者的临床疗效及更好地预测其预后。本文就慢性心力衰竭临床治疗及生物标志物的研究及展望作一综述。Chronic heart failure usually marks the end stage of most cardiovascular diseases,and has the characteristics of high prevalence and extremely unfavorable prognosis.In terms of drug therapy,the"Golden Triangle"program is widely regarded as a classic strategy for the treatment of chronic heart failure.In recent years,with the publication of a large number of clinical research data,the"new quadruple"therapy for chronic heart failure and the soluble guanylate cyclase agonist Vericiguat and other new therapeutic drugs began to be applied in the clinic.A series of biomarkers have been found that are closely related to the prognosis of patients with chronic heart failure,such as SERCA2a,neutrophil gelatinase-associated lipid carrier protein,and growth differentiation factor 15.The discovery of these new therapies and biomarkers could help improve clinical outcomes and better predict prognosis in patients with chronic heart failure.This article reviews the clinical treatment and biomarkers of chronic heart failure.

关 键 词：慢性心力衰竭 新四联疗法 鸟苷酸环化酶激动剂 SERCA2A 

分 类 号：R541.61[医药卫生—心血管疾病] R541.62[医药卫生—内科学]